Molecular Detection of GES-2 Extended Spectrum Beta-lactamase Producing Pseudomonas Aeruginosa in Pretoria, South Africa

Int J Antimicrob Agents. 2004 Jul;24(1):35-8. doi: 10.1016/j.ijantimicag.2003.12.012.

Abstract

Screening for and detection of the novel extended spectrum Beta-lactamase (ESBL), GES-2 produced by Pseudomonas aeruginosa remains a problem in the clinical microbiology laboratory. This study aimed to compare the normally used ESBL screening agent ceftazidime, with molecular detection, to demonstrate the presence of GES-2 ESBL production in clinical isolates of P. aeruginosa. Ceftazidime was found unreliable as an ESBL screening agent, with a specificity of 34.4%, when National Committee for Clinical Laboratory Standards resistance criteria for P. aeruginosa were employed. An improved PCR detection method was devised, that amplified a 371 bp segment of bla(GES-2). This should lead to more cost-effective DNA sequencing and sequence interpretation in the laboratory.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Base Sequence
  • DNA, Bacterial
  • Molecular Sequence Data
  • Pseudomonas aeruginosa / enzymology*
  • South Africa
  • beta-Lactamases / biosynthesis*

Substances

  • DNA, Bacterial
  • beta-lactamase GES-2
  • beta-Lactamases